Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo and ZYTIGA® plus prednisone (control arm).[i] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #9; Oral Abstract Session: Prostate Cancer, February 11, 12:45 PM-2:00 PM EST).The primary efficacy analysis showed median rPFS was extended by six months in patients treated in the combination arm compared with patients in the control arm (22.6 vs. 16.6 months; hazard ratio [HR] 0.69 [95% CI, 0.58-0.83]; p<0.0001). The HR for radiographic progression or death as assessed by blinded independent central review (BICR) was 0.864 [95% CI, 0.718–1.040]. According to an updated analysis performed at a median follow-up of 54.8 months, a 30 percent reduction in the risk of radiographic progression or death was shown in the combination arm...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Abiraterone Acetate | Actos | Allergy & Immunology | Anemia | Arrhythmia | Bilirubin | Brain | Breast Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Chemistry | Chemotherapy | Child Development | Children | Chronic Pain | Clinical Trials | Congestive Heart Failure | Corticosteroid Therapy | Cough | Diabetes | Drugs & Pharmacology | Endocrinology | Epilepsy | Food and Drug Administration (FDA) | Headache | Health Management | Heart | Heart Attack | Heart Disease | Heart Failure | Hematology | Hepatitis | Hepatitis Vaccine | Hormones | Hypertension | Hypothyroidism | Infectious Diseases | International Medicine & Public Health | Ketoconazole | Laboratory Medicine | Learning | Legislation | Liver | Marketing | Migraine | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Neurology | Neuroscience | Oral Cancer | Organic | Orthopaedics | Osteoporosis | Pain | Pain Management | Pharmaceuticals | Prednisolone | Prednisone | Pregnancy | Pregnancy and Breast Cancer | Profits and Losses | Prostate Cancer | Pulmonary Hypertension | Radiation Therapy | Radiography | Respiratory Medicine | Science | Skin | Statistics | Study | Thyroid | Thyroid Cancer | Toxicology | Universities & Medical Training | Urology & Nephrology | Vaccines | Ventricular Arrhythmia | Veterinary Vaccinations | Warnings | WHO